Assignee
ARCUS BIOSCIENCES INC
US·37 granted patents·18 pending applications·97 citations·filing 2017–2025
Top patents by PatentIndex Score
55 records- 0198US11001603B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2020·Granted May 11, 2021·13 cites·1 claims
- 0296US11633416B1Oral formulations of CD73 compoundsARCUS BIOSCIENCES INC·Filed 2021·Granted Apr 25, 2023·4 cites·24 claims
- 0396US10239912B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2017·Granted Mar 26, 2019·23 cites·47 claims
- 0495US11667662B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2021·Granted Jun 6, 2023·4 cites·9 claims
- 0595US10981944B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2019·Granted Apr 20, 2021·11 cites·20 claims
- 0694US12168023B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Granted Dec 17, 2024·1 cites·24 claims
- 0794US11787762B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alphaARCUS BIOSCIENCES INC·Filed 2022·Granted Oct 17, 2023·2 cites·26 claims
- 0893US11407712B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2αARCUS BIOSCIENCES INC·Filed 2021·Granted Aug 9, 2022·3 cites·15 claims
- 0992US12145901B1Process for preparing tetralin compoundsARCUS BIOSCIENCES INC·Filed 2022·Granted Nov 19, 2024·2 cites·25 claims
- 1092US10399962B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2018·Granted Sep 3, 2019·13 cites·25 claims
- 1191US11819512B2Solid forms of a CD73 inhibitor and the use thereofARCUS BIOSCIENCES INC·Filed 2019·Granted Nov 21, 2023·5 cites·17 claims
- 1290US11649261B2Crystalline forms of a CD73 inhibitor and uses thereofARCUS BIOSCIENCES INC·Filed 2021·Granted May 16, 2023·5 cites·23 claims
- 1388US12195447B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2021·Granted Jan 14, 2025·1 cites·2 claims
- 1487US11072597B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2019·Granted Jul 27, 2021·3 cites·14 claims
- 1586US12459967B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2023·Granted Nov 4, 2025·0 cites·11 claims
- 1686US12103907B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alphaARCUS BIOSCIENCES INC·Filed 2023·Granted Oct 1, 2024·0 cites·1 claims
- 1785US11058704B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2017·Granted Jul 13, 2021·4 cites·25 claims
- 1884US11820824B2Antibodies to TIGITARCUS BIOSCIENCES INC·Filed 2021·Granted Nov 21, 2023·1 cites·16 claims
- 1983US2025319113A1Inhibitors of adenosine 5'-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2082US2025214930A1Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alphaARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2179US11267845B2Inhibitors of CD73-mediated immunosuppressionARCUS BIOSCIENCES INC·Filed 2017·Granted Mar 8, 2022·1 cites·32 claims
- 2279US11045472B2Quinazoline-pyridine derivatives for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2018·Granted Jun 29, 2021·1 cites·20 claims
- 2378US12195482B1Compounds as inhibitors of AXLARCUS BIOSCIENCES INC·Filed 2024·Granted Jan 14, 2025·0 cites·2 claims
- 2473US12281136B2Crystalline forms of a CD73 inhibitor and uses thereofARCUS BIOSCIENCES INC·Filed 2023·Granted Apr 22, 2025·0 cites·19 claims
- 2572US12415854B2Antibodies to TIGITARCUS BIOSCIENCES INC·Filed 2023·Granted Sep 16, 2025·0 cites·19 claims
- 2672US12384773B2Thiazole compounds and methods of use thereofARCUS BIOSCIENCES INC·Filed 2024·Granted Aug 12, 2025·0 cites·14 claims
- 2770US11970543B2Anti-CD39 antibodies and use thereofARCUS BIOSCIENCES INC·Filed 2023·Granted Apr 30, 2024·0 cites·13 claims
- 2869US2025230173A1Salt forms of an axl inhibitorARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2968US2025084178A1Anti-cd39 antibodies and use thereofARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3067US2023416277A1Compounds as inhibitors of axlARCUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3166US2023338377A1Dosing with an azolopyrimidine compoundARCUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3264US2024180947A1Lyophilized formulations of cd73 compoundsARCUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3362US11478479B2Dosing with an azolopyrimidine compoundARCUS BIOSCIENCES INC·Filed 2019·Granted Oct 25, 2022·0 cites·25 claims
- 3462US2025011318A1Cbl-b inhibitors and methods of use thereofARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3562US2025179176A1Anti-tigit antibodies and uses of the sameARCUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3662US2024425497A1Cbl-b Inhibitors and Methods of Use ThereofARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3761US2026028336A1Cbl-b inhibitors and methods of use thereofARCUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3860US12071411B2Inhibitors of HIF-2α and methods of use thereofARCUS BIOSCIENCES INC·Filed 2022·Granted Aug 27, 2024·0 cites·31 claims
- 3960US11993584B2Solid forms of an azolopyrimidine compoundARCUS BIOSCIENCES INC·Filed 2019·Granted May 28, 2024·0 cites·21 claims
- 4057US2024124490A1Inhibitors of hpk1 and methods of use thereofARCUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4155US12453738B2Treatment of oncogene-driven cancersARCUS BIOSCIENCES INC·Filed 2020·Granted Oct 28, 2025·0 cites·8 claims
- 4255US2025375447A1Treatment of cancer utilizing an identified adenosine fingerprintARCUS BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4354US2024226115A1Axl inhibitor compoundsARCUS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4453US2024246967A1Axl compoundsARCUS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4553US2026042777A1Piperidylurea compounds and methods of use thereofARCUS BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4652US12310965B2Treatment of cancer utilizing an identified adenosine fingerprintARCUS BIOSCIENCES INC·Filed 2020·Granted May 27, 2025·0 cites·8 claims
- 4752US11931343B2CD73 inhibitorsARCUS BIOSCIENCES INC·Filed 2019·Granted Mar 19, 2024·0 cites·11 claims
- 4851US2022235031A1Processes for preparing aminopyrimidine compoundsARCUS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4951US2023024438A1Inhibitors of hif-2alphaARCUS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 5050US12226425B2Inhibitors of ARG1 and/or ARG2ARCUS BIOSCIENCES INC·Filed 2019·Granted Feb 18, 2025·0 cites·11 claims
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ARCUS BIOSCIENCES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →